These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 28831860)

  • 21. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
    Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
    Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Association Between Statin Use and Outcomes in Patients Initiating Androgen Deprivation Therapy.
    Hamilton RJ; Ding K; Crook JM; O'Callaghan CJ; Higano CS; Dearnaley DP; Horwitz EM; Goldenberg SL; Gospodarowicz MK; Klotz L
    Eur Urol; 2021 Apr; 79(4):446-452. PubMed ID: 33390282
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy.
    Sun M; Choueiri TK; Hamnvik OP; Preston MA; De Velasco G; Jiang W; Loeb S; Nguyen PL; Trinh QD
    JAMA Oncol; 2016 Apr; 2(4):500-7. PubMed ID: 26720632
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A simple prognostic model involving prostate-specific antigen, alkaline phosphatase and albumin for predicting the time required to progress to castration-resistant prostate cancer in patients who received androgen deprivation therapy.
    Lv W; Shang H; Pei X; Chen Y; Xie H; He D; Wang X; Li L
    Int Urol Nephrol; 2017 Jan; 49(1):61-67. PubMed ID: 27837416
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of microRNA-21 expression with clinicopathological characteristics and the risk of progression in advanced prostate cancer patients receiving androgen deprivation therapy.
    Guan Y; Wu Y; Liu Y; Ni J; Nong S
    Prostate; 2016 Aug; 76(11):986-93. PubMed ID: 27040772
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of statins on advanced prostate cancer patients with androgen deprivation therapy or abiraterone/enzalutamide: A systematic review and meta-analysis.
    Yang H; Pang L; Hu X; Wang W; Xu B; Zhang X; Liu L
    J Clin Pharm Ther; 2020 Jun; 45(3):488-495. PubMed ID: 31951037
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic Impact of Serum Testosterone and Body Mass Index Before Androgen-deprivation Therapy in Metastatic Prostate Cancer.
    Shiota M; Takeuchi A; Sugimoto M; Kashiwagi E; Dejima T; Kiyoshima K; Inokuchi J; Tatsugami K; Yokomizo A
    Anticancer Res; 2015 Dec; 35(12):6925-32. PubMed ID: 26637918
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database.
    Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
    BJU Int; 2012 Aug; 110(4):492-8. PubMed ID: 22094083
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association between use of β-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease.
    Grytli HH; Fagerland MW; Fosså SD; Taskén KA
    Eur Urol; 2014 Mar; 65(3):635-41. PubMed ID: 23351721
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The predictive value of ERG protein expression for development of castration-resistant prostate cancer in hormone-naïve advanced prostate cancer treated with primary androgen deprivation therapy.
    Berg KD; Røder MA; Thomsen FB; Vainer B; Gerds TA; Brasso K; Iversen P
    Prostate; 2015 Oct; 75(14):1499-509. PubMed ID: 26053696
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer.
    Gandaglia G; Sun M; Hu JC; Novara G; Choueiri TK; Nguyen PL; Schiffmann J; Graefen M; Shariat SF; Abdollah F; Briganti A; Montorsi F; Trinh QD; Karakiewicz PI
    Eur Urol; 2014 Dec; 66(6):1125-32. PubMed ID: 24495466
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-androgen monotherapy versus gonadotropin-releasing hormone agonists in men with advanced, non-metastatic prostate cancer: a register-based, observational study.
    Thomsen FB; Bosco C; Garmo H; Adolfsson J; Hammar N; Stattin P; Van Hemelrijck M
    Acta Oncol; 2019 Jan; 58(1):110-118. PubMed ID: 30375907
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Androgen deprivation therapy in patients with localized disease: Comparison with curative intent treatments and time to castration resistance. Results of the Spanish Prostate Cancer Registry.
    Garcia-Rodriguez J; Fernandez-Gomez JM; Cozar JM; Miñana B; Gomez-Veiga F; Rodriguez-Antolin A; ;
    Actas Urol Esp (Engl Ed); 2020 Apr; 44(3):156-163. PubMed ID: 32113829
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08.
    Voog JC; Paulus R; Shipley WU; Smith MR; McGowan DG; Jones CU; Bahary JP; Zeitzer KL; Souhami L; Leibenhaut MH; Rotman M; Husain SM; Gore E; Raben A; Chafe S; Sandler HM; Efstathiou JA
    Eur Urol; 2016 Feb; 69(2):204-10. PubMed ID: 26362090
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
    Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
    Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential Risk of Castration Resistance After Initial Radical Prostatectomy or Radiotherapy for Prostate Cancer.
    Obata H; Shiota M; Akitake N; Takeuchi A; Kashiwagi E; Dejima T; Kiyoshima K; Inokuchi J; Tatsugami K; Eto M
    Anticancer Res; 2017 Oct; 37(10):5631-5637. PubMed ID: 28982880
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy.
    Jackson WC; Schipper MJ; Johnson SB; Foster C; Li D; Sandler HM; Palapattu GS; Hamstra DA; Feng FY
    Eur Urol; 2016 Jan; 69(1):50-7. PubMed ID: 26004800
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association between ischaemic bowel syndromes and androgen deprivation therapy in patients with prostate cancer: a retrospective cohort study.
    Chiang IN; Huang CY; Pu YS; Chang CH; Muo CH; Chung CJ; Wang RY; Young TH
    BMJ Open; 2017 Feb; 7(2):e012950. PubMed ID: 28246133
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors predicting progression to castrate-resistant prostate cancer in patients with advanced prostate cancer receiving long-term androgen-deprivation therapy.
    de la Taille A; Martínez-Piñeiro L; Cabri P; Houchard A; Schalken J;
    BJU Int; 2017 Jan; 119(1):74-81. PubMed ID: 26919403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.